Moolec Science (MLEC)
Food ingredients through molecular farming, fermentation, and plant-protein production.
Something off on this page? Send us feedback.
Supplies food manufacturers with texturized plant proteins, fungal-biomass protein, specialty oils, and related services while developing crop-based and fermented protein platforms. Revenue comes from goods and services in a single science-based food-ingredients segment.
Combines commercially available texturized soy and chickpea ingredients with Mycofood, a fermented fungal-biomass protein, and GLASO, a safflower-derived specialty oil. The business also provides research, scale-up, and manufacturing services to food-industry customers.
Its molecular-farming platform develops crop-based proteins and oils, while precision fermentation supports controlled microbial production. Operations span Argentina, the United States, Finland, Brazil, and the United Kingdom, with the United States as the principal market focus.
Commercial progress depends on crop and fermentation scale-up, traceability, processing capacity, consistent specifications, customer qualification, and food and feed permissions. Piggy Sooy, PEEA1, and the chymosin platform remain in development; the company operates as one science-based food-ingredients segment.
Company facts
Categories
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $1.1M · Total debt $66.5M · Total assets $103.4M · Shareholders' equity $9.2M
- Revenue
- $2.6M
- Operating income
- −$2.1M
- Net income
- −$2.4M
No dividends on record.
| Institutions3 holders · as of Mar 31, 2026 | 3.85% | 16.6K shares | |
| Insiders1 holder · as of Mar 18, 2026 | — | 1.9K shares |
institutions as of Mar 31, 2026 · holders as of their latest filing
No reliable share count is available for this listing, so stakes are shown as shares, not percentages.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
The institutional percentage is the one reported with the filings, not one recomputed on the share count here.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
HRT Financial LPInstitution | — | 16,575 | 13Fas of Mar 31, 2026 |
Estrada Gloria MontaronInsiderofficer: General Counsel | — | 1,909 | Form 4filed Mar 18, 2026 ↗ |
UBS Group AGInstitution | — | 2 | 13Fas of Mar 31, 2026 |
Sbi Securities Co., Ltd.Institution | — | 1 | 13Fas of Mar 31, 2026 |
Llodra Diego Juan AbelleyraInsiderdirector | — | 0 | Form 4filed Mar 18, 2026 ↗ |
| See all 16 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
Nothing filed in the last 12 months.
- Archer Daniels Midland
Direct scaled rival in textured soy and alternative proteins.
- Bunge
Direct rival in textured soy proteins and plant-based food inputs.
- International Flavors & Fragrances
Scale alternative in soy and pea proteins plus formulation systems.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Moolec Science | $7.27 | +6.75% | $4.9M | — | — | 0.0 | — |
| Archer Daniels Midland | $85.40 | +0.02% | $41.15B | 23.4 | 14.7 | 0.5 | +7.1% |
| Bunge | $123.70 | +0.68% | $23.60B | 23.9 | 11.5 | 0.3 | +88.3% |
| International Flavors & Fragrances | $86.94 | +0.02% | $22.20B | 80.5 | 25.5 | 2.2 | −29.3% |
| Median | 23.9 | 14.7 | 0.5 | +7.1% |